LFST
LifeStance Health Group, Inc.
LFST has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over LFST overall, supported by stronger fundamentals and stronger modeled upside.
LFST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
LFST's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LFST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 54x | $14.15 | — |
| Current | 74x | $14.15 | — |
| Cheap | 95x | $17.99 | +27% |
| Fair | 128x | $24.39 | +72% |
| Expensive | 319x | $60.61 | +328% |
Historical ranges are pointers, not guarantees.
LFST has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LFST Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for LFST, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
LFST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.26 | +39% |
| Q3 2026 | $0.19 | +$0.21 |
| Q2 2026 | $0.13 | +$0.17 |
| Q1 2026 | $0.06 | +$0.15 |
| Q4 2025 | $0.02 | +$0.17 |
LFST has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
LFST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $455.9M | +25% |
| Q2 2026 | $435.4M | +26% |
| Q1 2026 | $403.5M | +21% |
| Q4 2025 | $382.2M | +17% |
| Q3 2025 | $363.8M | +16% |
| Q2 2025 | $345.3M | +11% |
| Q1 2025 | $333M | +11% |
| Q4 2024 | $325.5M | +16% |
LFST's revenue has grown year over year every quarter since early 2021: $456M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.3% | +5.2 points |
| Q2 2026 | 7% | +7.9 points |
| Q1 2026 | 5.5% | +5 points |
| Q4 2025 | 4.7% | +4.4 points |
| Q3 2025 | 2% | +2 points |
| Q2 2025 | -0.8% | +4.3 points |
| Q1 2025 | 0.5% | +6.1 points |
| Q4 2024 | 0.3% | +12 points |
LFST has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LFST on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
LFST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $22.4M | +32% |
| Q2 2026 | $87.9M | +55% |
| Q1 2026 | $22.3M | +$32.6M |
| Q4 2025 | $46.6M | -17% |
| Q3 2025 | $17M | -3.8% |
| Q2 2025 | $56.6M | +45% |
| Q1 2025 | -$10.3M | +$16.7M |
| Q4 2024 | $56M | +941% |
LFST generated $179M in free cash flow over the past year, up 50% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
LFST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +3.9M shares |
| 1 year | +0.6% | +2.3M shares |
| 3 years | +4.7% | +17.6M shares |
LFST has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $24.8M |
| Q2 2026 | $48.5M |
| Q1 2026 | $49.1M |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LFST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 5.5x | High |
| Q4 2024 | 14.6x | High |
LFST's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over LFST on leverage, with a lower net debt burden relative to earnings.
LFST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.6 | Overbought |
| Stochastic | 75.0 | Neutral |
LFST's weekly RSI is 72 (overbought) and its Stochastic is 75 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LFST PE vs Healthcare Sector
| Metric | LFST | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 188% above |
| PE % | 3 | 37 | 34 pts below |
LFST is trading at 74x earnings, a 188% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over LFST on valuation relative to its sector.
LFST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.8 | 11% above |
| 20 week MA | $12.2 | 16% above |
| 50 week MA | $9.22 | 53% above |
| 100 week MA | $7.67 | 84% above |
| 200 week MA | $7.24 | 95% above |
LFST is in an uptrend: it's above all five of its weekly moving averages, and 95% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
LFST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $10.1 | -58% |
| 2022 | $10.1 | $4.62 | -54% |
| 2023 | $4.62 | $7.83 | +69% |
| 2024 | $7.83 | $7.49 | -4.3% |
| 2025 | $7.49 | $7.13 | -4.8% |
| 2026 YTD | $7.13 | $14.2 | +98% |
LFST is up 98% so far in 2026, after finishing lower in four of the previous five years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LFST on returns for 2026, with the stronger performance.